Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies

Table 1

Summary of nonengraftment cellular therapy results.

Author	Number of patients	Conditioning regimen	Number of CD3 cells infused	Response rate (CR/PR)
Colvin et al. [16]	19 patients (AML/NHL only)	100 cGy TBI	1 × 10^6–2 × 10^8/kg	37% (26%/11%)
Guo et al. [17]	30 patients (AML)	Mitoxantrone 8–10 mg/m^2 (3 days) and cytarabine 150 mg/m^2 (7 days)	0.5–2.6 × 10^8/kg	80% (80%/NR)
*O’Donnell et al. [18]	4 patients (ALL, MDS)	Fludarabine 30 mg/m^2, 200 cGy TBI, Post transplant ± Pretransplant cyclophosphamide	2.6–3.8 × 10^7/kg	75% (75%/0%)
*Dey et al. [19]	22 patients (NHL, HL, Multiple Myeloma)	Cyclophosphamide 50 mg/kg (3-4 days), ATG 15–30 mg/kg (3-4 days), and anti-CD 2 monoclonal antibody	1 × 10^7–2.98 × 10^8/kg	41% (18%/22%)

*Only patients who did not engraft in this study are included in the results. AML= acute myeloid leukemia, NHL= non-Hodgkins lymphoma, MDS= myelodysplastic syndrome, ALL= acute lymphocytic leukemia, HL= Hodgkins lymphoma.